BioNTech SE American Depositary Share (BNTX) DIvidends Date & History

Key Takeaways

• BioNTech SE (BNTX) currently offers no dividend yield, with a payout ratio of 0.00%.
• The company paid a one-time special dividend of approximately $2.11 per share in June 2022, but has not distributed dividends since.
• Strong balance sheet with €17.2 billion in cash and equivalents as of December 2025 supports potential future payouts, though negative free cash flow reflects heavy R&D spending.
• BNTX's dividend profile aligns with growth-focused biotech peers like Moderna (MRNA) and Vertex (VRTX), both at 0% yield.
• No announcements indicate plans for regular dividends, prioritizing pipeline development over shareholder payouts.

Dividend Overview

BioNTech SE, a clinical-stage biotechnology company pioneering mRNA therapies, does not pay a regular dividend. The current trailing annual dividend yield stands at 0.00%, with no forward dividend rate established. The firm issued a special dividend of $2.11 per American Depositary Share (ADR) on June 17, 2022, following ex-dividend date of June 2, 2022, capitalizing on COVID-19 vaccine profits. Since then, payments have ceased, positioning BNTX as a non-dividend stock rather than a high-yield or growth dividend play. This approach is typical for biotech firms reinvesting earnings into research and development (R&D) amid an expansive oncology and infectious disease pipeline.

Dividend History and Growth

BioNTech's dividend history is limited to the 2022 special payout, with no prior or subsequent regular distributions recorded on platforms like Nasdaq or Yahoo Finance. There is no dividend growth streak, as payments have been irregular and absent post-2022. The company's investor relations page details ADR dividend handling by BNY Mellon but notes no ongoing policy. This reflects a long-term strategy of capital retention to fuel innovation, rather than consistent shareholder returns through escalating dividends.

Dividend Sustainability and Payout Ratio

With no current dividend, sustainability metrics like payout ratio are effectively 0.00%, posing no immediate risk. BioNTech maintains robust financial health, holding €17.2 billion in cash, cash equivalents, and securities at year-end 2025, alongside minimal debt of €267 million and a current ratio of 7.54. However, trailing twelve-month levered free cash flow is negative at -$1.1 billion, driven by substantial R&D investments exceeding operating cash flow of $456 million. Earnings coverage is strong in theory due to ample liquidity, but negative profitability in recent quarters underscores a focus on growth over distributions. Initiation of dividends would depend on pipeline commercialization and sustained profitability.

Dividend Compared to Industry Peers

BioNTech's 0.00% yield mirrors many clinical-stage biotech peers emphasizing growth. For instance, Moderna (MRNA) and Vertex Pharmaceuticals (VRTX) also pay no dividends, prioritizing R&D. Regeneron (REGN) offers a modest 0.5% yield with quarterly payments of about $0.94 per share. More mature players like Gilead Sciences (GILD) provide 2.5% yield ($3.28 annual), and Amgen (AMGN) around 3% ($10.08 annual), reflecting established revenue streams. BNTX's profile suits investors tolerant of zero income in favor of capital appreciation potential versus income-oriented biotech names.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is particularly useful for identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research workflow.

Is This Stock Attractive for Dividend Investors?

BioNTech SE (BNTX) may not appeal to traditional dividend investors seeking current income, given its zero yield and lack of regular payouts. Income-focused or conservative investors prioritizing steady cash flows might look elsewhere, as the absence of dividends since the 2022 special payment highlights a reinvestment strategy. However, growth-oriented dividend investors could find appeal in BNTX's potential for future distributions. With €17 billion in liquidity and a low-debt profile, the company is financially positioned to initiate dividends if its mRNA oncology pipeline yields commercial successes, shifting toward maturity like peers REGN or GILD. Long-term holders betting on biotech innovation may view the non-dividend status as temporary, balancing high risk with upside from pipeline advancements. Overall, suitability hinges on tolerance for volatility over immediate yields.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations